Drug Trial Radar · NCT05499260
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Aug 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
70
Planned (sponsor's estimate)
Start
May 2, 2022
Primary completion
Mar 2, 2023
Study completion Mar 2, 2023
Sponsor
- Lead sponsor
- Shanghai Zhimeng Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Epilepsy.
Conditions
- Healthy Volunteers
Interventions
CB03-154Drug
CB03-154 tablet once daily.
PlaceboDrug
Placebo tablet once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of CB03-154 following single and multiple ascending oral dose administration.Time frame: rom the signing of the consent form until 30 days following the last dose of the study drug
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Frontage Clinical Services, Inc.
Secaucus, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.